Novo Nordisk has patented antibodies targeting transthyretin (TTR) for treating TTR-related diseases like amyloidosis. The antibodies can diagnose, inhibit aggregation, and reduce TTR accumulation. The patent claims a specific antibody structure. GlobalData’s report on Novo Nordisk gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Novo Nordisk, was a key innovation area identified from patents. Novo Nordisk's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies binding to human transthyretin for treating ttr amyloidosis
A recently granted patent (Publication Number: US11912759B2) discloses an antibody designed to bind to human transthyretin. The antibody comprises specific amino acid sequences in its heavy chain variable region and light chain variable region. The patent claims cover various aspects of the antibody, including its isotype (IgG1, IgG2, or IgG4), structure (intact antibody or binding fragment), fusion with constant regions, and mutant forms for reduced binding to Fc? receptors. Additionally, the patent includes claims related to pharmaceutical compositions containing the antibody, nucleic acids encoding the antibody's heavy and light chains, recombinant expression vectors, host cells transformed with the vectors, and methods for producing and using the antibody.
Furthermore, the patent claims encompass methods for treating transthyretin-mediated amyloidosis in a subject by administering the antibody. It also extends to treating various conditions such as cardiomyopathy, familial amyloid polyneuropathy, central nervous system selective amyloidosis, osteoarthritis, rheumatoid arthritis, and age-related macular degeneration with the antibody. The patent provides a comprehensive coverage of the antibody's design, production, and therapeutic applications, highlighting its potential in addressing a range of diseases and disorders associated with transthyretin and beyond.
To know more about GlobalData’s detailed insights on Novo Nordisk, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
